Erythropoiesis-stimulating agents in allogeneic and autologous hematopoietic stem cell transplantation

Bibliography

• Gratwohl A, Baldomero H, Aljurf M, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA 2010;303:1617-24
   PubMed Web of Science ®Google Scholar
• Passweg JR, Baldomero H, Peters C, et al. Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplant 2014;49(6):744-50
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Baldomero H, Passweg J. Hematopoietic stem cell transplantation activity in Europe. Curr Opin Hematol 2013;20(6):485-93
   PubMed Web of Science ®Google Scholar
• Thomas ED. A history of allogeneic hematopoietic cell transplantation. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG, editors. Thomas’ hematopoietic cell transplantation. 4th Edition. Wiley-Blackwell Publishing Chichester; West Sussex, UK: 2009. p. 3-7
   Google Scholar
• Holtick U, Albrecht M, Chemnitz JM, et al. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. Cochrane Database Syst Rev 2014;4:CD010189
   PubMed Web of Science ®Google Scholar
• Aapro M. An update on twenty years of anemia management with erythropoiesis-stimulating agents in nephrology and oncology/hematology.Oncologist. 2009;14(Suppl 1):1-5
   Google Scholar
• Rodgers GMIII, Becker PS, Blinder M, et al. Cancer-and chemotherapy-induced anemia. J Natl Compr Canc Netw 2012;10(5):628-53
   PubMed Web of Science ®Google Scholar
• Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 2008;111(1):25-41. Review. Erratum in: Blood. 2008 Apr 1;111(7):3909
   PubMed Web of Science ®Google Scholar
• Eschbach JW, Detter JC, Adamson JW. Physiologic studies in normal and uremic sheep. II. Changes in erythropoiesis and oxygen transport. Kidney Int 1980;18(6):732-45
   PubMed Web of Science ®Google Scholar
• Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987;316(2):73-8
   PubMed Web of Science ®Google Scholar
• Lin FK, Suggs S, Lin CH, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985;82(22):7580-4
   PubMed Web of Science ®Google Scholar
• Cazzola M, Ponchio L, Beguin Y, et al. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders: results of a phase I/II clinical trial. Blood 1992;79:29-37
   PubMed Web of Science ®Google Scholar
• Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non platinum chemotherapy: results of a randomized, double-blind, placebo controlled trial. J Clin Oncol 2001;19:2865-74
   PubMed Web of Science ®Google Scholar
• Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95(4):888-95
   PubMed Web of Science ®Google Scholar
• Bohlius J, Langensiepen S, Schwarzer G, et al. Erythropoietin for patients with malignant disease. Cochrane Database Syst Rev 2004(3):CD003407
   Google Scholar
• Bohlius J, Langensiepen S, Schwarzer G, et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 2005;97:489-98
   PubMed Web of Science ®Google Scholar
• Dunst J. Management of anemia in patients undergoing curative radiotherapy. Erythropoietin, transfusions, or better nothing? Strahlenther Onkol 2004;180:671-81
   PubMed Web of Science ®Google Scholar
• Fallowfield L, Gagnon D, Zagari M, et al. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. Br J Cancer 2002;87(12):1341-53
   PubMed Web of Science ®Google Scholar
• Rodriguez Garzotto A, Heine O, Turner M, et al. Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience. J Blood Med 2014;5:43-8
   Google Scholar
• Bohlius J, Tonia T, Nüesch E, et al. Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data. Br J Cancer 2014;111(1):33-45
   PubMed Web of Science ®Google Scholar
• Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet 2007;369(9572):1502-4
   PubMed Web of Science ®Google Scholar
• Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12(2):231-42
   PubMed Web of Science ®Google Scholar
• Pedrazzoli P, Farris A, Del Prete S, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 2008;26(10):1619-25
   PubMed Web of Science ®Google Scholar
• Pedrazzoli P, Rosti G, Secondino S, et al. Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia. Cancer 2009;115(6):1169-73
   PubMed Web of Science ®Google Scholar
• Glaspy J. Update on safety of ESAs in cancer-induced anemia. J Natl Compr Canc Netw 2012;10(5):659-66
   PubMed Web of Science ®Google Scholar
• Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010;102(2):301-15
   PubMed Web of Science ®Google Scholar
• Hedenus M, Osterborg A, Tomita D, et al. Effects of erythropoiesis-stimulating agents on survival and other outcomes in patients with lymphoproliferative malignancies: a study-level meta-analysis. Leuk Lymphoma 2012;53(11):2151-8
   PubMed Web of Science ®Google Scholar
• Miller CB, Lazarus HM. Erythropoietin in stem cell transplantation. Bone Marrow Transplant 2001;27(10):1011-16
   PubMed Web of Science ®Google Scholar
• Schapira L, Antin JH, Ransil BJ, et al. Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. Blood 1990;76(11):2354-9
   PubMed Web of Science ®Google Scholar
• Beguin Y, Clemons GK, Oris R, et al. Circulating erythropoietin levels after bone marrow transplantation: inappropriate response to anemia in allogeneic transplants. Blood 1991;77:868-73
   PubMed Web of Science ®Google Scholar
• Miller CB, Jones RJ, Zahurak ML, et al. Impaired erythropoietin response to anemia after bone marrow transplantation. Blood 1992;10:2677-82
   Google Scholar
• Abedi MR, Backman L, Bostrom M, et al. Markedly increased serum erythropoietin levels following conditioning for allogeneic bone marrow transplantation. Bone Marrow Transplant 1990;6:121
   PubMed Web of Science ®Google Scholar
• Widness JA, Schmidt RL, Hohl RJ, ET AL. Change in erythropoietin pharmacokinetics following hematopoietic transplantation. Clin Pharmacol Ther 2007;81(6):873-9
   PubMed Web of Science ®Google Scholar
• Holler E, Kolb HJ, Möller A, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990;75(4):1011-16
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Grossi A, Bosi A, et al. Impaired erythropoietin production in mice treated with cyclosporin A. Blood 1991;78(6):1615-18
   PubMed Web of Science ®Google Scholar
• Yeo EJ, Ryu JH, Cho YS, et al. Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1. Blood 2006;107(3):916-12
   PubMed Web of Science ®Google Scholar
• Beguin Y, Oris R, Fillet G. Dynamics of erythropoietic recovery after bone marrow transplantation: role of marrow proliferative capacity and erythropoietin production in autologous vs allogeneic transplants. Bone Marrow Transplant 1993;11:285-92
   PubMed Web of Science ®Google Scholar
• Beguin Y, Baron F, Fillet G. Influence of marrow erythropoietic activity on serum erythropoietin levels after autologous hematopoietic stem cell transplantation. Haematologica 1998;83:1076-81
   PubMed Web of Science ®Google Scholar
• Baron F, Fillet G, Beguin Y. Erythropoiesis after non myeloablative stem-cell transplantation is not impaired by inadequate erythropoietin production as observed after conventional allogeneic transplantation. Transplantation 2002;74:1692-6
   PubMed Web of Science ®Google Scholar
• Calabrich A, Katz A. Management of anemia in cancer patients. Future Oncol 2011;7(4):507-17
   PubMed Web of Science ®Google Scholar
• Spivak JL, Gascon P, Ludwig H. Anemia management in oncology and hematology. Oncologist 2009;14(Suppl 1):43-56
   PubMed Web of Science ®Google Scholar
• Gajewski JL, Johnson VV, Sandler SG, et al. A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation. Blood 2008;112(8):3036
   PubMed Web of Science ®Google Scholar
• Kumar R, Gupta M, Gupta V, et al. Acute Transfusion Reactions (ATRs) in Intensive Care Unit (ICU): a Retrospective Study. J Clin Diagn Res 2014;8(2):127-9
   Google Scholar
• Shaz BH, Francis RO, Hillyer CD. Transfusion-associated graft-versus-host disease and microchimerism. In: Murphy MF, Pamphilon DH, Heddle NM, editors. Practical transfusion medicine. Fourth edition. John Wiley & Sons, Ltd; Oxford, UK: 2013, 10.1002/9781118520093.ch11
   Google Scholar
• Popovsky MA, Chaplin HCJr, Moore SB. Transfusion-related acute lung injury: a neglected, serious complication of hemotherapy. Transfusion 1992;32:589-92
   PubMed Web of Science ®Google Scholar
• Radia R, Pamphilon D. Transfusion strategies in patients undergoing stem-cell transplantation. Expert Rev Hematol 2011;4:213-20
   PubMed Web of Science ®Google Scholar
• Dicato M, Plawny L, Diederich M. Anemia in cancer. Ann Oncol 2010;21(Suppl 7):VII167-72
   PubMedGoogle Scholar
• European Directorate for Quality of Medicines and Healthcare, Strasbourg. EU Guide to Preparation, Use and Quality Assurance of Blood Components 2010
   Google Scholar
• Pullarkat V, Blanchard S, Tegtmeier B, et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2008;42(12):79
   Web of Science ®Google Scholar
• Maradei SC, Maiolino A, de Azevedo AM, et al. Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation. Blood 2009;114(6):1270
   PubMed Web of Science ®Google Scholar
• Mahindra A, Bolwell B, Sobecks R, et al. Elevated pretransplant serum ferritin is associated with inferior survival following nonmyeloablative allogeneic transplantation. Br J Haematol 2009;146(3):310
   PubMed Web of Science ®Google Scholar
• Pavenski K, Saidenberg E, Lavoie M, et al. Red blood cell storage lesions and related transfusion issues: a Canadian Blood Services research and development symposium. Transfus Med Rev 2012;26(1):68-84
   PubMed Web of Science ®Google Scholar
• Carson JL, Grossman BJ, Kleinman S, et al. Red blood cell transfusion: a clinical practice guideline from the AABB. Clinical Transfusion Medicine Committee of the AABB. Ann Intern Med 2012;157(1):49-58
   PubMed Web of Science ®Google Scholar
• Kader AS, Lim JT, Berthelet E, et al. Prognostic significance of blood transfusions in patients with esophageal cancer treated with combined chemoradiotherapy. Am J Clin Oncol 2007;30:492-7
   PubMed Web of Science ®Google Scholar
• Atzil S, Arad M, Glasner A, et al. Blood transfusion promotes cancer progression: a critical role for aged erythrocytes. Anesthesiology 2008;109:989-97
   PubMed Web of Science ®Google Scholar
• Khorana AA, Francis CW, Blumberg N, et al. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 2008;168:2377-81
   PubMed Web of Science ®Google Scholar
• Vekeman F, Bookhart BK, White J, et al. Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin. Transfusion 2009;49(5):895-902
   PubMed Web of Science ®Google Scholar
• Lyman GH, Glaspy J. Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review. Cancer 2006;106:223-33
   PubMed Web of Science ®Google Scholar
• Bohlius J, Wilson J, Seidenfeld J, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2006(3):CD007303
   Google Scholar
• Grant MD, Piper M, Bohlius J, et al. Epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment: comparative effectiveness update. Agency for Healthcare Research and Quality (US); Rockville (MD): 2013; Comparative Effectiveness Reviews, No. 113
   Google Scholar
• Storring PL, Tiplady RJ, Gaines Das RE, et al. Epoetinalfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 1998;100(1):79-89
   PubMed Web of Science ®Google Scholar
• Egrie JC, Dwyer E, Browne JK, et al. Darbepoetinalfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003;31:290-9
   PubMed Web of Science ®Google Scholar
• Glaspy J, Tchekmedyian NS. Darbepoetinalfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy. Oncology 2002;16(Suppl 11):23-9
   PubMedGoogle Scholar
• Weigang-Köhler K, Vetter A, Thyroff-Friesinger U. HX575, recombinant human epoetinalfa, for the treatment of chemotherapy-associated symptomatic anaemia in patients with solid tumours. Onkologie 2009;32(4):168-74
   PubMed Web of Science ®Google Scholar
• Barosi G, Bosi A, Abbracchio MP, et al. Key concepts and critical issues on epoetin and filgrastimbiosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica 2011;96(7):937-42
   PubMed Web of Science ®Google Scholar
• Tzekova V, Mihaylov G, Elezovic I, et al. Epoetin Zeta Oncology Study Group. Therapeutic effects of epoetin zeta in the treatment of chemotherapy-induced anaemia. Curr Med Res Opin 2009;25(7):1689-97
   PubMed Web of Science ®Google Scholar
• Klaesson S, Ringden O, Ljungman P, et al. Reduced blood transfusions requirements after allogeneic bone marrow transplantation: results of a randomised, double-blind study with high-dose erythropoietin. Bone Marrow Transplant 1994;13:397-402
   PubMed Web of Science ®Google Scholar
• Steegman J, Lopez J, Otero M, et al. Erythropoietin treatment in allogeneic BMT accelerates erythroid reconstitution: results of a prospective controlled randomized trial. Bone Marrow Transplant 1992;10:541-6
   PubMed Web of Science ®Google Scholar
• Biggs JC, Atkinson KA, Booker V, et al. Prospective randomised double-blind trial of the in vivo use of recombinant human erythropoietin in bone marrow transplantation from hla-identical sibling donors. The australian bone marrow transplant study group. Bone Marrow Transplant 1995;15(1):129-34
   PubMed Web of Science ®Google Scholar
• Link H, Boogaerts MA, Fauser AA, et al. A controlled trial of recombinant human erythropoietin after bone marrow transplantation. Blood 1994;84(10):3327-35
   PubMed Web of Science ®Google Scholar
• Arnold R, Schmeiser T, Heit W, et al. Hemopoietic reconstitution after bone marrow transplantation. Exp Hematol 1986;14:271
   PubMed Web of Science ®Google Scholar
• Ivanov V, Faucher C, Mohty M, et al. Early administration of recombinant erythropoietin improves hemoglobin recovery after reduced intensity conditioned allogeneic stem cell transplantation. Bone Marrow Transplant 2005;36(10):901-6
   PubMed Web of Science ®Google Scholar
• Michallet M, Goldet K, Sobh M, et al. Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. Cancer 2013;119(1):107-14
   PubMed Web of Science ®Google Scholar
• Gaya A, Urbano-Ispizua A, Fernandez-Aviles F, et al. Anemia associated with impaired erythropoietin secretion after allogeneic stem cell transplantation: incidence, risk factors, and response to treatment. Biol Blood Marrow Transplant 2008;14(8):880-7
   PubMed Web of Science ®Google Scholar
• Baron F, Sautois B, Baudoux E, et al. Optimization of recombinant human erythropoietin therapy after allogeneic hematopoietic stem cell transplantation. Exp Hematol 2002;30:546-54
   PubMed Web of Science ®Google Scholar
• Baron F, Frere P, Beguin Y. Once weekly recombinant human erythropoietin therapy is very efficient after allogeneic peripheral blood stem cell transplantation when started soon after engraftment. Haematologica 2003;88(6):718-20
   PubMedGoogle Scholar
• Vanstraelen G, Baron F, Willems E, et al. Recombinant human erythropoietin therapy after allogeneic hematopoietic cell transplantation with a non myeloablative conditioning regimen: low donor chimerism predicts for poor response. Exp Hematol 2006;34:841-50
   PubMed Web of Science ®Google Scholar
• Jaspers A, Baron F, Willems E, et al. Erythropoietin therapy after allogeneic hematopoietic cell transplantation: a prospective randomized trial. Blood 2014;124(1):33-41
   PubMed Web of Science ®Google Scholar
• Lemoli RM, Tafuri A, Fortuna A, et al. Cycling status of CD34+ cells mobilized into peripheral blood of healthy donors by recombinant human granulocyte colony-stimulating factor. Blood 1997;89:1189-96
   PubMed Web of Science ®Google Scholar
• Pene R, Appelbaum FR, Fisher L, et al. Use of granulocyte-macrophage colony-stimulating factor and erythropoietin in combination after autologous marrow transplantation. Bone Marrow Transplant 1993;11:219-22
   PubMed Web of Science ®Google Scholar
• Ayash LJ, Elias A, Hunt M, et al. Recombinant human erythropoietin for the treatment of the anaemia associated with autologous bone marrow transplantation. Br J Haematol 1994;87(1):153-61
   PubMed Web of Science ®Google Scholar
• Chao NJ, Schriber JR, Long GD, et al. A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin’s and non-Hodgkin’s lymphoma undergoing autologous bone marrow transplantation. Blood 1994;83(10):2823-8
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Bosi A, Ieri A, et al. Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial. Bone Marrow Transplant 1996;17:527-31
   PubMed Web of Science ®Google Scholar
• Baron F, Frere P, Fillet G, et al. Tandem high-dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion. Br J Haematol 2003;123(1):103-5
   PubMed Web of Science ®Google Scholar
• Martino M, Oliva E, Console G, et al. Administration of recombinant human erythropoietin alpha before autologous stem cell transplantation reduces transfusion requirement in multiple myeloma patients. Support Care Cancer 2005;13(3):182-7
   PubMed Web of Science ®Google Scholar
• Hunault-Berger M, Tanguy-Schmidt A, Rachieru P, et al. brHuEpo before high-dose therapy allows autologous peripheral stem-cell transplantation without red blood cell transfusion: a pilot study. Bone Marrow Transplant 2005;35(9):903-7
   PubMed Web of Science ®Google Scholar
• Baron F, Frere P, Fillet G, et al. Recombinant human erythropoietin therapyis very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment. Clin Cancer Res 2003;9:5566-72
   PubMed Web of Science ®Google Scholar
• Vanstraelen G, Baron F, Frère P, et al. Efficacy of recombinant human erythropoietin therapy started one month after autologous peripheral blood stem cell transplantation. Haematologica 2005;90(9):1269-70
   PubMed Web of Science ®Google Scholar
• Beguin Y, Maertens J, De PB, et al. Darbepoetin-alfa and I.V. iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial. Am J Hematol 2013;88(12):990-6
   PubMed Web of Science ®Google Scholar
• Locatelli F, Zecca M, Pedrazzoli P, et al. Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: effect on erythroid repopulation in autologous vs allogeneic transplants. Bone Marrow Transplant 1994;13:403-10
   PubMed Web of Science ®Google Scholar
• Locatelli F, Zecca M, Ponchio L, et al. Pilot trial of combined administration of erythropoietin and granulocyte colony-stimulating factor to children undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 1994;14(6):929-35
   PubMed Web of Science ®Google Scholar
• Beguin Y. Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. Haematologica 2002;87:1209-21
   PubMed Web of Science ®Google Scholar
• Ludwig H, Müldür E, Endler G, Hübl W. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol 2013;24:1886-92
   PubMed Web of Science ®Google Scholar
• Petrelli F, Borgonovo K, Cabiddu M, et al. Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. J Cancer Res Clin Oncol 2012;138:179-87
   PubMed Web of Science ®Google Scholar
• Chertow GM, Mason PD, Vaage-Nilsen O, Ahlme´n J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006;21:378-82
   PubMed Web of Science ®Google Scholar
• Yuan L, Geng L, Ge L, et al. Effect of iron liposomes on anemia of inflammation. Int J Pharm 2013;454:82-9
   PubMed Web of Science ®Google Scholar
• Auerbach M, Strauss W, Auerbach S, et al. Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min. Am J Hematol 2013;88:944-7
   PubMed Web of Science ®Google Scholar
• Portenoy RK. Cancer-related fatigue: an immense problem. Oncologist 2000;5(5):350-2
   PubMedGoogle Scholar
• Christodoulou C, Dafni U, Aravantinos G, et al. Effects of epoetin alpha on quality of life of cancer patients with solid tumors receiving chemotherapy. Anticancer Res 2009;29:693-702
   PubMed Web of Science ®Google Scholar
• Glaspy JA, Charu V, Luo D, et al. Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms. Cancer 2009;115:1121-31
   PubMed Web of Science ®Google Scholar
• Minton O, Richardson A, Sharpe M, et al. A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst 2008;100:1155-66
   PubMed Web of Science ®Google Scholar
• Tonelli M, Hemmelgarn B, Reiman T, et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 2009;180:E62-71
   PubMed Web of Science ®Google Scholar
• Bohlius J, Tonia T, Nüesch E, et al. Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data. Br J Cancer 2014;111(1):33-45
   PubMed Web of Science ®Google Scholar
• Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997;34(3 Suppl 2):13-19
   PubMed Web of Science ®Google Scholar
• Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis- stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009;373:1532-42
   PubMed Web of Science ®Google Scholar